It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Score ...

Earnings Estimate Revisions Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this ...

Core Viewpoint - Vertex Pharmaceuticals has experienced significant revenue growth and regulatory approvals, particularly in the cystic fibrosis market, while also expanding its pipeline into non-CF therapies [1][2][3]. Group 1: Cystic Fibrosis Market - Vertex holds a dominant position in the cystic fibrosis (CF) market, with sales driven by its triple therapy, Trikafta (Kaftrio in Europe), and recent label expansions to younger age groups [2]. - Trikafta sales are expected to continue growing due to strong uptake in both U.S. and ex-U.S. markets, supported by reimbursements and expanded use [2]. - The stock has risen 31.2% over the past year, contrasting with a 10.0% decline in the industry [4]. Group 2: Non-CF Pipeline Developments - Vertex has achieved rapid success with its non-CF pipeline, particularly with the approval of Casgevy, a one-shot gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) [3][5]. - Casgevy is the first CRISPR/Cas9-based therapy approved globally, with an estimated patient population of around 35,000 in the U.S. and Europe [5]. - Vertex is making progress with the launch of Casgevy, having activated over 25 authorized treatment centers and established contracts in the U.S. commercial market [6]. Group 3: Upcoming Product Launches - Vertex plans to launch suzetrigine for acute pain and vanzacaftor triple for CF, with optimism for both products to be launched this year [7]. - The NDA submission process for suzetrigine is underway, targeting moderate-to-severe acute pain, with a pivotal phase III program planned for diabetic peripheral neuropathy in late 2024 [8]. - Data from phase II studies indicate a promising safety and efficacy profile for suzetrigine, which could transform pain treatment paradigms [9]. Group 4: Strategic Acquisitions and Future Potential - Vertex announced a $4.9 billion agreement to acquire Alpine Immune Sciences, which will enhance its pipeline with povetacicept, targeting serious autoimmune diseases [13]. - Povetacicept is set to enter late-stage development for IgA nephropathy in the second half of 2024, with potential applications in other autoimmune renal diseases [13]. - Vertex has a robust mid- to late-stage pipeline in various disease areas, representing multibillion-dollar opportunities, with several important clinical milestones expected in the next 12 months [12].

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D. Founded in 1989, Vertex's rollercoaster story is most iconically characterized by the rise and fall of Incivek, a hepatitis C drug that reached $1 billion in sales faster than any before it, only to be withdrawn from the market just three years afte ...

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity.However, Vertex Pharmaceuticals (VRTX 0.91%), a drugmaker with a monopoly in the cystic fibrosis (CF) market, hasn't done that -- quite the contrary. Since it launched its first CF product some 12 years ago, the biotech hasn't ...

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharmaceuticals Incorporated UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ ...

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 56% year over year, driven by higher product revenues, lower costs and a lower tax rate in the quarter.The company reported total revenues of $2.69 billion, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.56 billion. Total revenues rose 13% year over year, primarily driven by high ...

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Charles Wagner - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Jessica Fye - JPMorgan Chase & Co. Salveen Richter - Goldman Sachs Group Olivia Brayer - Cantor Fitzgerald & Co. Liisa Bayko - Evercore ISI Terence Flynn - Morgan Stanley Debjit Chattopadhyay - ...